Small molecule protein kinase inhibitors approved by regulatory agencies outside of the United States

Abstract

Owing to genetic alterations and overexpression, the dysregulation of protein kinases plays a significant role in the pathogenesis of many autoimmune and neoplastic disorders and protein kinase antagonists have become an important drug target. Although the efficacy of imatinib in the treatment of chronic myelogenous leukemia in the United States in 2001 was the main driver of protein kinase inhibitor drug discovery, this was preceded by the approval of fasudil (a ROCK antagonist) in Japan in 1995 for the treatment of cerebral vasospasm. There are 21 small molecule protein kinase inhibitors that are approved in China, Japan, Europe, and South Korea that are not approved in the United Sates and 75 FDA-approved inhibitors in the United States. Of the 21 agents, eleven target receptor protein-tyrosine kinases, eight inhibit nonreceptor protein-tyrosine kinases, and two block protein-serine/threonine kinases. All 21 drugs are orally bioavailable or topically effective. Of the non-FDA approved drugs, sixteen are prescribed for the treatment of neoplastic diseases, three are directed toward inflammatory disorders, one is used for glaucoma, and fasudil is used in the management of vasospasm. The leading targets of kinase inhibitors approved by both international regulatory agencies and by the FDA are members of the EGFR family, the VEGFR family, and the JAK family. One-third of the 21 internationally approved drugs are not compliant with Lipinski's rule of five for orally bioavailable drugs. The rule of five relies on four parameters including molecular weight, number of hydrogen bond donors and acceptors, and the Log of the partition coefficient.

Keywords: Apatinib (PubMED CID: 11315474); Breast cancer; Catequentinib (PubMED CID: 25017411); Chronic myelogenous leukemia; Delgocitinib (PubMED CID: 50914062); Fasudil (PubMED CID: 3547); Filgotinib (PubMED CID: 49831257); Icotinib (PubMED CID: 22024915); Imatinib (PubMED CID: 123596); Lipinski rule of five; Lipophilic efficiency; Non-small cell lung cancer; Orally bioavailable; Peficitinib (PubMED CID: 57928403); Pyrotinib (PubMED CID: 51039030); Tirabrutinib (PubMED CID: 54755438).